Key regions: Brazil, India, Australia, United States, United Kingdom
Antiviral drugs have been in high demand globally due to the COVID-19 pandemic. Northern Africa, being a region that is not immune to the virus, has also experienced a surge in the demand for these drugs.
Customer preferences: Customers in Northern Africa have shown a preference for antiviral drugs that have been approved by regulatory bodies such as the FDA and EMA. They also prefer drugs that have been proven effective in clinical trials and have minimal side effects. Additionally, customers prefer drugs that are affordable and easily accessible.
Trends in the market: The antiviral drugs market in Northern Africa has seen an increase in the production and distribution of generic drugs. This is due to the high cost of patented drugs, which makes them less accessible to the majority of the population. There has also been an increase in the use of combination therapies, which involve the use of two or more antiviral drugs to treat a single infection. This is because combination therapies have been shown to be more effective in treating viral infections than single-drug therapies.
Local special circumstances: Northern Africa has a high prevalence of viral infections such as HIV, hepatitis B and C, and influenza. This has led to an increased demand for antiviral drugs in the region. Additionally, the region has a high population density, which makes it easier for viral infections to spread. This has further increased the demand for antiviral drugs.
Underlying macroeconomic factors: The antiviral drugs market in Northern Africa is influenced by factors such as government policies, healthcare infrastructure, and economic stability. Government policies that promote the production and distribution of generic drugs have led to increased accessibility and affordability of antiviral drugs. Additionally, the region's healthcare infrastructure plays a crucial role in the availability and distribution of antiviral drugs. Economic stability also plays a role in the affordability of these drugs, as customers are more likely to purchase them when they are financially stable.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
